Bronchioloalveolar carcinoma: A review of the epidemiology, pathology, and treatment

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 3, 2005, Pages 342-352

  Jackman, David M ^a,b   Chirieac, Lucian R ^b   Jänne, Pasi A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Bronchioloalveolar; Carcinoma; Epidermal growth factor; Non small cell lung; Receptor; Smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PLATINUM DERIVATIVE;

ASPIRATION BIOPSY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG SENSITIVITY; DRUG TOLERABILITY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; MUCINOUS CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; REVIEW; RISK FACTOR; TRACHEOBRONCHIAL TOILET;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; LUNG NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS;

EID: 22144465514     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-871993     Document Type: Review

References (81)

1. Liebow AA. Bronchiolo-alveolar carcinoma. Adv Intern Med 1960;10:329-3S8
2. Travis WD. World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon Oxford: IARC Press, Oxford University Press (distributor); 2004
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30
4. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068
5. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994;73:1163-1170
6. Auerbach O, Garfinkel L. The changing pattern of lung carcinoma. Cancer 1991;68:1973-1977
7. Hsu CP, Chen CY, Hsu NY. Bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995;110:374-381
8. Harpole DH, Bigelow C, Young WG Jr, Wolfe WG, Sabiston DC Jr. Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients. Ann Thorac Surg 1988; 46:502-507
9. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75(1 Suppl):191-202
10. Read WL, Page NC, Tierney RM, Piccirillo JF, Govindan R. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004;45:137-142
11. Falk RT, Pickle LW, Fontham ET, et al. Epidemiology of bronchioloalveolar carcinoma. Cancer Epidemiol Biomarkers Prev 1992;1:339-344
12. Rolen KA, Fulton JP, Tamura DJ, Strauss GM. Bronchioloalveolar carcinoma (BAC) of the lung is related to cigarette smoking: A case-control study from Rhode Island (RI) [abstract 2711]. Proc Am Soc Clin Oncol 2003;22:674
13. Morabia A, Wynder EL. Relation of bronchioloalveolar carcinoma to tobacco. BMJ 1992;304:541-543
14. Morton WE, Treyve EL. Histologic differences in occupational risks of lung cancer incidence. Am J Ind Med 1982;3: 441-457
15. Rothschild H, Mulvey JJ. An increased risk for lung cancer mortality associated with sugarcane farming. J Natl Cancer Inst 1982;68:755-760
16. Palmarini M, Fan H. Retrovirus-induced ovine pulmonary adenocarcinoma: an animal model for lung cancer. J Natl Cancer Inst 2001;93:1603-1614
17. Sharp JM. Sheep pulmonary adenomatosis: a contagious tumour and its cause. Cancer Surv 1987;6:73-83
18. Sigurdsson B. Adenomatosis of sheep's lungs: experimental transmission. Arch Gesamte Virusforsch 1958;8:51-58
19. Palmarini M, Sharp JM, de las Heras M, Fan H. Jaagsiekte sheep retrovirus is necessary and sufficient to induce a contagious lung cancer in sheep. J Virol 1999;73:6964-6972
20. Garcia-Goti M, Gonzalez L, Cousens C, et al. Sheep pulmonary adenomatosis: characterization of two pathological forms associated with Jaagsiekte retrovirus. J Comp Pathol 2000;122:55-65
21. De las Heras M, Barsky SH, Hasleton P, et al. Evidence for a protein related immunologically to the Jaagsiekte sheep retrovirus in some human lung tumours. Eur Respir J 2000; 16:330-332
22. Travis W, Colby T, Corrin B, et al. The World Health Organization Histological Typing of Lung and Pleural Tumors. 3rd ed. Berlin: Springer Verlag; 1999
23. Clayton F. Bronchioloalveolar carcinomas: cell types, patterns of growth, and prognostic correlates. Cancer 1986;57:1555-1564
24. Daly RC, Trastek VF, Pairolero PC, et al. Bronchioloalveolar carcinoma: factors affecting survival. Ann Thorac Surg 1991;51:368-376 discussion 376-377
25. Greco RJ, Steiner RM, Goldman S, Cotler H, Patchefsky A, Cohn HE. Bronchioloalveolar cell carcinoma of the lung. Ann Thorac Surg 1986;41:652-656
26. Manning JT Jr, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma: the significance of two histopathologic types. Cancer 1984;54:525-534
27. Matthews MJ, Mackay B, Lukeman J. The pathology of non-small cell carcinoma of the lung. Semin Oncol 1983;10:34-55
28. Travis WD. Pathology of lung cancer. Clin Chest Med 2002; 23:65-81
29. Singh G, Katyal SL. Clara Cell Proteins. Ann N Y Acad Sci 2000;923:43-58
30. Singh G, Katyal SL, Torikata C. Carcinoma of type II pneumocytes: PAS staining as a screening test for nuclear inclusions of surfactant specific apoprotein. Cancer 1982;50: 946-948
31. Sidhu GS, Wieczorek R, Cassai ND, Zhu CC. The concept of bronchioloalveolar cell adenocarcinoma: redefinition, a critique of the 1999 WHO classification, and an ultrastructural analysis of 155 cases. Int J Surg Pathol 2003;11: 89-99
32. Bennett DE, Sasser WF. Bronchiolar carcinoma: a valid clinicopathologic entity? A study of 30 cases. Cancer 1969;24: 876-887
33. Greenberg SD, Smith MN, Spjut HJ. Bronchiolo-alveolar carcinoma: cell of origin. Am J Clin Pathol 1975;63:153-167
34. Copin MC, Buisine MP, Leteurtre E, et al. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol 2001;32:274-281
35. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol 2002;10:97-102
36. Shah RN, Badve S, Papreddy K, Schindler S, Laskin WB, Yeldandi AV. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. Hum Pathol 2002;33:915-920
37. Saad RS, Cho P, Silverman JF, Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol 2004;122:421-427
38. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol 2004;35:3-7
39. Simsir A, Wei XJ, Yee H, Moreira A, Cangiarella J. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens. Am J Clin Pathol 2004;121:350-357
40. Lau SK, Desrochers MJ, Luthringer DJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol 2002;15:538-542
41. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol 2001;116:319-325
42. Johansson L. Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 2004;8:259-267
43. Jerome Marson V, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology 2004;45:125-134
44. Awaya H, Takeshima Y, Yamasaki M, Inai K. Expression of MUC1, MUC2, MUCSAC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 2004; 121:644-653
45. Westra WH. Early glandular neoplasia of the lung. Respir Res 2000;1:163-169
46. Lee KS, Kim Y, Han J, Ko EJ, Park CK, Primack SL. Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings. Radiographics 1997;17:1345-1357
47. Breathnach OS, Ishibe N, Williams J, Linnoila RI, Caporaso N, Johnson BE. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer 1999;86:1165-1173
48. Hiratsuka T, Mukae H, Ihiboshi H, et al. Severe bronchorrhea accompanying alveolar cell carcinoma: treatment with clarithromycin and inhaled beclomethasone. Nihon Kokyuki Gakkai Zasshi 1998;36:482-487
49. Hidaka N, Nagao K. Bronchioloalveolar carcinoma accompanied by severe bronchorrhea. Chest 1996;110:281-282
50. Dwek JH, Charytan C, Stachura I, Kaganowicz A. Salt-wasting bronchorrhea and its mechanisms. Arch Intern Med 1977;137:791-794
51. Homma S, Kawabata M, Kishi K, et al. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest 1999;115: 1465-1468
52. Marom ZM, Goswami SK. Respiratory mucus hypersecretion (bronchorrhea): a case discussion-possible mechanisms(s) and treatment. J Allergy Clin Immunol 1991;87:1050-1055
53. Chang GC, Yang TY, Wang NS, Huang CM, Chiang CD. Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients. J Formos Med Assoc 2003;102:407-411
54. Milton DT, Kris MG, Gomez JE, Feinstein MB. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Support Care Cancer 2005;13:70-72
55. Takao M, Inoue K, Watanabe F, et al. Successful treatment of persistent bronchorrhea by gefitinib in a case with recurrent bronchioloalveolar carcinoma: a case report. World J Surg Oncol 2003;1:8
56. Yano S, Kanematsu T, Miki T, et al. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa"). Cancer Sci 2003;94:453-458
57. Chetty KG, Dick C, McGovern J, Conroy RM, Mahutte CK. Refractory hypoxemia due to intrapulmonary shunting associated with bronchioloalveolar carcinoma. Chest 1997; 111:1120-1121
58. Barlesi F, Doddoli C, Thomas P, Kleisbauer JP, Giudicelli R, Fuentes P. Bilateral bronchioloalveolar lung carcinoma: is there a place for palliative pneumonectomy? Eur J Cardiothorac Surg 2001;20:1113-1116
59. Trigaux JP, Gevenois PA, Goncette L, Gouat F, Schumaker A, Weynants P. Bronchioloalveolar carcinoma: computed tomography findings. Eur Respir J 1996;9:11-16
60. Regnard JF, Santelmo N, Romdhani N, et al. Bronchioloalveolar lung carcinoma: results of surgical treatment and prognostic factors. Chest 1998;114:45-50
61. Breathnach OS, Kwiatkowski DJ, Finkelstein DM, et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg 2001;121:42-47
62. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002;74:1640-1646 discussion 1646-1647
63. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-2852
64. Rena O, Papalia E, Ruffini E, et al. Stage I pure bronchioloalveolar carcinoma: recurrences, survival and comparison with adenocarcinoma of the lung. Eur J Cardiothorac Surg 2003;23:409-414
65. Yamato Y, Tsuchida M, Watanabe T, et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001;71:971-974
66. Watanabe S, Watanabe T, Arai K, Kasai T, Haratake J, Urayama H. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg 2002;73:1071-1075
67. Feldman ER, Eagan RT, Schaid DJ. Metastatic bronchioloalveolar carcinoma and metastatic adenocarcinoma of the lung: comparison of clinical manifestations, chemotherapeutic responses, and prognosis. Mayo Clin Proc 1992;67:27-32
68. Sorensen JB, Hirsch FR, Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization: an analysis of 259 consecutive patients with advanced disease. Cancer 1988;62:361-367
69. Miller VA, Kris MG, Shah N, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bonchioalveolar cell carcinoma (BAC): preliminary results of a phase II trial [abstract 2491]. Proc Am Soc Clin Oncol 2003;22:619
70. Janne PA, Ostler PA, Lucca J, et al. ZD1839 ("Iressa") shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol. Proc Am Soc Clin Oncol 2002;21:319
71. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected]. J Clin Oncol 2003;21:2237-2246
72. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109
73. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158
74. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
75. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
76. Natale RB, Shak S, Aronson N, et al. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: predicting response to gefitinib, an EGFR kinase inhibitor [abstract 763]. Proc Am Soc Clin Oncol 2003;22:190
77. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-865
78. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346
79. Kris MG, Sandler A, Miller VA, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC) [abstract 7062]. Proc Am Soc Clin Oncol 2004;22:14S
80. West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 [abstract 7014]. Proc Am Soc Clin Oncol 2004;22:14S
81. Jackman DJ, Lucca J, Fidias P, et al. Phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma [abstract 7148]. Proc Am Soc Clin Oncol 2005